Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-11-25
2000-03-14
Rotman, Alan L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546297, 5462837, A61K 3144, C07D21172, C07D40112, C07D40512, C07D40912
Patent
active
060373563
ABSTRACT:
Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: ##STR1## wherein X is O or NR.sup.9 and Het, R.sup.1, R.sup.7, R.sup.8, R.sup.12 -R.sup.15, R.sup.a, R.sup.b, R.sup.c, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.
REFERENCES:
patent: 4418052 (1983-11-01), Wong
patent: 4980148 (1990-12-01), Dean
patent: 5011686 (1991-04-01), Pang
patent: 5024829 (1991-06-01), Berger et al.
patent: 5466811 (1995-11-01), Alexander
patent: 5656600 (1997-08-01), Abelman et al.
Powers, W. J. et al., "Indium-111 platelet scintigraphy in cerebrovascular disease," Neurology 32:938-943 (1982).
Saulnier, M. G. et al., "An efficient method for the synthesis of guanidino prodrugs," Bioorg. Med. Chem. Lett. 4:1985-1990 (1994).
Thakur, M. L. et al., "Indium-111 labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions," Thrombosis Res. 9:345-357 (1976).
Kim, K. S. et al., "Preparation of Argatroban Analog Thrombin Inhibitors with Reduced Basic Guanidine Moiety, And Studies of Their Cell Permeability and Antithrombotic Activities," Med. Chem. Res. 6:377-383 (1996).
Lefkovits, J., and Topol, E. J., "Direct Thrombin Inhibitors in Cardiovascular Medicine," Circulation 90:1522-1536 (1994).
Mack, H. et al., "Design, synthesis and biological activity of novel rigid amidino-phenylalanine derivatives as inhibitors of thrombin," J. Enzyme Inhibition 9:73-86 (1995).
Edwards, P. D. et al., "Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl .alpha.-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole," J. Am. Chem. Soc. 114:1854-1863 (1992).
Harker, L. A., "Strategies for inhibiting the effects of thrombin," Blood Coagulation and Fibrinolysis 5:S47-S58 (1994).
Jeong, J.-H. et al., "Cyclic Guanidino-Sugars with Low pK, as Transition-State Analog Inhibitors of Glycosidases: Neutral Instead of Charged Species Are the Active Forms," J. Am. Chem. Soc. 118:4227-4234 (1996).
Coughlin, S. R., "Molecular Mechanisms of Thrombin Signaling," Seminars in Hematology 31:270-277 (1994).
Cuypers, H. T. et al., "Sulfhydryl Content of Borine Eye Lens Leucine Aminopeptidase. The determination of the reactivity of the sulfhydryl groups of the zinc metalloenzyme, of the enzyme activated by Mg.sup.2+, Mn.sup.2+, and Co.sup.2+, and of the metal-free apoenzyme," J. Biol. Chem. 257:7086-7091 (1982).
de Roos, A. et al., "Myocardial infarct sizing and assessment of reperfusion by magnetic resonance imaging: a review," Int. J. Cardiac Imaging 7:133-138 (1991).
Barrett, A.J., "Proteinase inhibitors: potential drugs?" in Enzyme Inhibitors as Drugs, Sandler, M., ed., The Macmillan Press Ltd., London, England, pp.219-229 (1980).
Brown, F. J. et al., "Design of Orally Active, Non-Peptidic Inhibitors of Human Leukocyte Elastase," J. Med. Chem. 37:1259-1261 (1994).
Claeson, G., "Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system," Blood Coagulation and Fibrinolysis 5:411-436 (1994).
Lu Tianbao
Markotan Thomas P.
Siedem Colleen
Tomczuk Bruce E.
3-Dimensional Pharmaceuticals Inc.
Desai Rita
Rotman Alan L.
LandOfFree
Heteroaryl aminoguanidines and alkoxyguanidines and their use as does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl aminoguanidines and alkoxyguanidines and their use as, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl aminoguanidines and alkoxyguanidines and their use as will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-169528